the opposite side is injected with the same number of units to maintain facial symmetryfollow-the-pain injections in areas where the individual reports that pain exists (additional sites in V1, V2, V3, and temporalis): 2.5 to 5 units at each site Between 50 and 100 units used every 3 months, although individuals have benefited from lower doses Dose adjustments can be made depending on clinical response or facial weakness
Dizziness, trouble walking normally, anxiety, jitters, weakness, and uncoordinated movements are a few examples of these signs
Contraindications: Hypersensitivity to Hydroxocobalamin or to any of the excipients
Skip to product information FAQ Key Questions No
Calculation habit: Label the vial immediately after reconstitution with the total volume, calculated concentration, and date
Each COA reports results from third-party laboratory analysis, including: High-performance liquid chromatography (HPLC) for purity, typically confirmed at 99% or higher Liquid chromatography mass spectrometry (LC-MS) for molecular identity and mass confirmation Sterility and endotoxin screening where applicable Chemical contaminant and residual solvent checks COAs are sourced from independent certified labs rather than in-house testing alone, giving researchers a verifiable record of molecular integrity for each batch
